Kelly Lantz (@KellyLeonPSU) header
Kelly Lantz (@KellyLeonPSU) profile picture

Kelly Lantz

@KellyLeonPSU

Consultant - Hematology Oncology | Ph.D. @PennStHershey 🔬 | B.S. @PennStateBerks 🏈 | Cat and Dog Mom 🐱🐶

 Pittsburgh
Joined March 2018
  • Tweets141
  • Following594
  • Followers230
8Media
Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)Photo by Kelly Lantz (@KellyLeonPSU)
Had a great time at #ASCO22 in the beautiful city of Chicago. Looking forward to #ASCO23!
Image from Kelly Lantz (@KellyLeonPSU)
Image from Kelly Lantz (@KellyLeonPSU)
5
It’s that time of the Twitter cycle again! 🐦 This is news to me, but apparently my own institution doesn’t even think I rate “Dr.”
This Post is from an account that no longer exists. Learn more
9
1
3
21
#AACR22 Analysis 2: Several preclinical updates were presented describing two different dual-targeting strategies for r/r NHL and two approaches for developing switchable CAR-Ts. Celltelligence provides insights and context for each presentation: bit.ly/CT-523794
Image from celltelligence (@celltelligence)
1
Sad to not be joining my colleagues in-person at #AACR2022 but excited to virtually attend presentations. Happy Day 1 of AACR!
Image from Kelly Lantz (@KellyLeonPSU)
1
On Thursday, March 10, $PSTX released their Q4 2021 results (press release) highlighting their anticipated clinical updates for 2022, while expressing their interest in partnering their emerging technologies: bit.ly/CT-511599
Image from celltelligence (@celltelligence)
3
4
And leaving the bench doesn’t mean you don’t see cool, exciting science happening every day. I love my non-academic, non-bench career (plus the perks of traveling, a work/life balance, and better pay)
Ricardo Mondragon-Gonzalez (@RicMG90) profile pictureRicardo Mondragon-Gonzalez@RicMG906 Mar 2022
Leaving academia doesn't mean leaving science. Science in industry is exciting too. Joining a biotech/pharma does not mean your creativity is discouraged, quite the opposite.
1
4
Leaving academia doesn't mean leaving science. Science in industry is exciting too. Joining a biotech/pharma does not mean your creativity is discouraged, quite the opposite.
10
62
24
635
It’s a little gloomy in Atlanta but it has been a great start to #ASH21
Image from Kelly Lantz (@KellyLeonPSU)
5
.@KellyLeonPSU et al. @airdlab demonstrate that DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A. bit.ly/36vfSn1 Part of the Year in Cell Biology: 2021 bit.ly/3rtllGF #CellBio2021
Image from Journal of Cell Biology (@JCellBiol)
5
13
An amazing read! Enjoyed @carlhjune’s highlight on these findings at #SITC21
Berger Lab (@berger_lab) profile pictureBerger Lab@berger_lab2 Dec 2021
Our newest paper is out in @CellCellPress today! Our postdoc @charlyryangood in collaboration with Angela Aznar and Shun Kuramitsu from the @carlhjune lab identify new features and regulators of CAR T cell exhaustion! @PennCDB @PennEpiInst #immunotherapy #CART 🧬🔬
We are pleased to present The Year in Cell Biology: 2021 collection, highlighting some of the outstanding research published over the last year in JCB. We hope you enjoy reading the collection and welcome your comments! bit.ly/3rtllGF #CellBio2021
Image from Journal of Cell Biology (@JCellBiol)
2
20
5
63
Feels great to be back at an in-person conference and running into @esd5psu #SITC21
Erika Dahl, PhD (@esd5psu) profile pictureErika Dahl, PhD@esd5psu14 Nov 2021
Look who I found @KellyLeonPSU #SITC21 👩🏼‍🔬👩🏻‍🔬
Image from Erika Dahl, PhD (@esd5psu)
1
#NEWS: Today, the @US_FDA granted approval for the first and only #CARTcell therapy for adult patients (18+) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. #ALL

1
15
4
39
Kelly Lantz retweeted
Trebak Lab (@TrebakM) profile picture
Trebak Lab@TrebakM26 Aug 2021
The Trebak lab @PittVMI is looking for a talented postdoc with expertise in either imaging/patch clamp/molecular biology/biochemistry/signaling…Please pass on. If interested please send CV to [email protected]
2
39
4
46
Based on the recent news, I really hope we will see a greater crackdown on PIs that: -are guilty of discrimination/harassment -pressure to fabricate data -make lab members compete against each other on the same project -force lab members work insane hours
16
158
28
1,470
Thank you @IoanaOlan and @narita_lab for a beautifully written spotlight on our work!
Journal of Cell Biology (@JCellBiol) profile pictureJournal of Cell Biology@JCellBiol13 Jul 2021
.@IoanaOlan and Narita @narita_lab preview a study from @KellyLeonPSU et al. @airdlab (bit.ly/36vfSn1) that shows that DOT1L is an epigenetic regulator of the IL1A gene during #oncogene-induced #senescence. bit.ly/2U4Pb5S #epigenetics
Image from Journal of Cell Biology (@JCellBiol)
1
8
My student asked me: “Why doesn’t it count if I say that you are doing a great job?”. I have wanted to write about this and act on this for the longest time. A 🧵 about why I think we should introduce accountability for being “a good mentor” in Academia. 1/n
21
129
54
710
Check out Aflah’s, and others, wonderful piece on how her gender identity shaped her experiences in STEM! Inclusion and diversity are very much important in STEM fields!! @CellPressNews @PennStHershey #DiversityandInclusion
Cell (@CellCellPress) profile pictureCell@CellCellPress25 Jun 2021
Replying to @CellCellPress
Aflah Hanafiah is a graduate student working in the Zhonghua Gao lab at @BMB_PSU where she studies the roles of PRC1 during early development. Read her piece, “A long road to becoming” spkl.io/601943M7J #CellPressPride #PrideInStem
As a trans Muslim scientist, I could say that the reason you can hear my voice now is my sheer determination and resilience, but in truth, it would have easily been silenced had I not received opportunities and support to realize my ambitions.

ALT As a trans Muslim scientist, I could say that the reason you can hear my voice now is my sheer determination and resilience, but in truth, it would have easily been silenced had I not received opportunities and support to realize my ambitions.

Check our latest manuscript. Great work from Fraser Millar @frmillar. Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer biorxiv.org/content/10.1101/…
Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer

Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer

Targeting early-stage lung cancer is vital to improve overall survival. We previously identified Toll-like receptor 2 (TLR2) as a regulator of oncogene-induced senescence (OIS) and the senescence-a...

biorxiv.org
10
11
1
38
DOT1L modulates the #senescence-associated secretory phenotype through epigenetic regulation of IL1A, say @KellyLeonPSU, @airdlab and colleagues. bit.ly/3bX40gK #Cellcycle #Chromatin #epigenetics
Image from Journal of Cell Biology (@JCellBiol)
5
9
Load more